Entera Bio Ltd. (ENTX)
ENTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/0001178913-26-001797-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ENTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | 2018 |
| SEC CIK | 0001638097 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $42K |
| Net income | -$11.4M |
| Operating income | -$11.5M |
| Net margin | -27235.7% |
| Operating margin | -27450.0% |
| Revenue growth | -76.8% |
| Cash | $7.1M |
| Total assets | $16.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 12521.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $265.9M cash; operating cash flow -$3.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 174,137,771 (2026-11-02); 45,857,242 a year earlier; 28,813,952 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-08-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-04-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $141K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$15.6M | -$7.4M | $265.9M | $378K | $0 | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $0 | -$7.3M | -$3.5M | $11.3M | $284K | $0 | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $0 | -$3.5M | -$3.1M | $4.1M | $567K | $0 | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $0 | -$3.0M | -$1.8M | $7.1M | $393K | $42K | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $0 | -$3.2M | -$2.5M | $8.6M | $527K | $124K | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $0 | -$2.7M | -$1.6M | $10.9M | $524K | $166K | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $42K | -$2.6M | -$1.4M | $12.6M | $515K | $223K | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $82K | -$2.4M | -$1.5M | $8.7M | $0 | $181K | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-28 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-06 |
| Latest proxy | DEF 14A | 2026-10-14 |
Source: SEC EDGAR submissions feed, 421 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.0% |
| 1 month | +24.9% |
| 3 months | +8.4% |
| Year to date | +60.3% |
| 1 year | +13.5% |
| From 52-week high | -20.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| VALN | Valneva SE | $5.65 | -0.18% | $536.1M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier